Results 161 to 170 of about 2,182,759 (269)
Software-Enhanced Drugs™: The third platform reshaping drug development. [PDF]
Proc Natl Acad Sci U S ALakhan SE, Wicks P.
europepmc +1 more source
Molecular Oncology, EarlyView.Combining PTEN protein assessment and transcriptomic profiling of prostate tumors, we uncovered a network enriched in senescence and extracellular matrix (ECM) programs associated with PTEN loss and conserved in a mouse model. We show that PTEN‐deficient cells trigger paracrine remodeling of the surrounding stroma and this information could help ...
Ivana Rondon‐Lorefice +16 more
wiley +1 more source
Role of Angiogenesis in Retinal Diseases and New Advances in Drug Development. [PDF]
CellsBoey E, Zaidi H, Tang T, Yazdanyar A.
europepmc +1 more source
Next‐generation proteomics improves lung cancer risk prediction
Molecular Oncology, EarlyView.This is one of very few studies that used prediagnostic blood samples from participants of two large population‐based cohorts. We identified, evaluated, and validated an innovative protein marker model that outperformed an established risk prediction model and criteria employed by low‐dose computed tomography in lung cancer screening trials.
Megha Bhardwaj +4 more
wiley +1 more source
Navigating Drug-Drug Interactions in Clinical Drug Development: A Tutorial. [PDF]
Clin Transl SciLohy Das J +2 more
europepmc +1 more source
Potential therapeutic targeting of BKCa channels in glioblastoma treatment
Molecular Oncology, EarlyView.This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak +4 more
wiley +1 more source
Enzyme inhibition in drug discovery and development. The good and the bad.
, 2010 Maria Paola Costi
openalex +1 more source